 |
|
|
| |
Cisgender women in seven African countries prefer long-acting injectable to daily oral PrEP for HIV prevention
|
| |
| |
IAS 2023 Press Release
Nearly eight out of 10 cisgender women prefer long-acting injectable cabotegravir to daily oral PrEP for HIV prevention, a study conducted in seven African countries found.
The study was an open-label extension of HPTN 084, a landmark clinical trial which demonstrated that long-acting injectable cabotegravir is superior to daily oral PrEP for HIV prevention in individuals assigned female at birth. Based on those results, long-acting injectable PrEP is now poised to be rolled out in multiple African countries.
This follow-up study, presented by Sinead Delany-Moretlwe of the University of the Witwatersrand, took place in Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda and Zimbabwe. It found that of nearly 2,500 participants, 78% chose long-acting PrEP while 22% chose daily oral PrEP.
A variety of factors influenced product choice, including personal preference regarding whether to get an injection every eight weeks or take a pill each day. Participants who chose long-acting PrEP were more likely to be sexually active but not live with a partner, to have experienced recent physical intimate partner violence and to have been paid for sex.
"These results suggest that long-acting PrEP could have a huge prevention impact in Africa, where uptake of daily oral PrEP has been disappointingly low," Lewin said. "I hope these findings will accelerate momentum to make long-acting PrEP accessible to all those who need it."
Abstract and session: Initial PrEP product choice: results from the HPTN 084 open-label extension, HIV prevention: Novel approaches and promising findings (5998)
|
| |
|
|
|
|
|
